Expression of Human CD46 Modulates Inflammation Associated With GalTKO Lung Xenograft Injury

Evaluation of lungs from GalTKO.hCD46 pigs, genetically modified to lack the galactose‐α(1,3)‐galactose epitope (GalTKO) and to express human CD46, a complement regulatory protein, has not previously been described. Physiologic, hematologic and biochemical parameters during perfusion with heparinized fresh human blood were measured for 33 GalTKO.hCD46, GalTKO (n = 16), and WT pig lungs (n = 16), and 12 pig lungs perfused with autologous pig blood. Median GalTKO.hCD46 lung survival was 171 min compared to 120 for GalTKO (p = 0.27) and 10 for WT lungs (p < 0.001). Complement activation, platelet activation and histamine elaboration were significantly reduced during the first 2 h of perfusion in GalTKO.hCD46 lungs compared to GalTKO (ΔC3a at 120′ 812 ± 230 vs. 1412 ± 1047, p = 0.02; ΔCD62P at 120′ 9.8 ± 7.2 vs. 25.4 ± 18.2, p < 0.01; Δhistamine at 60′ 97 ± 62 vs. 189 ± 194, p = 0.03). We conclude that, in addition to significant down‐modulation of complement activation, hCD46 expression in GalTKO lungs diminished platelet and coagulation cascade activation, neutrophil sequestration and histamine release. Because GalTKO.hCD46 lung failure kinetics correlated directly with platelet and neutrophil sequestration, coagulation cascade activation and a rise in histamine levels within the first hour of perfusion, further progress will likely depend upon improved control of these pathways, by rationally targeted additional modifications to pigs and pharmacologic interventions.

[1]  G. Snell,et al.  Sustained function of genetically modified porcine lungs in an ex vivo model of pulmonary xenotransplantation. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[2]  H. Tai,et al.  In vitro investigation of pig cells for resistance to human antibody‐mediated rejection , 2008, Transplant international : official journal of the European Society for Organ Transplantation.

[3]  R. Pierson,et al.  Xenogeneic lung transplantation models. , 2012, Methods in molecular biology.

[4]  D. Sachs,et al.  Results of Gal‐Knockout Porcine Thymokidney Xenografts , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  H. Schuurman,et al.  Transgenic expression in pig hearts of both human decay-accelerating factor and human membrane cofactor protein does not provide an additional benefit to that of human decay-accelerating factor alone in pig-to-baboon xenotransplantation. , 2004, Transplantation.

[6]  R. Pierson,et al.  Life-supporting function of genetically modified swine lungs in baboons. , 2007, The Journal of thoracic and cardiovascular surgery.

[7]  M. Stegall,et al.  The effect of anti-alphaGal antibody removal with immunoabsorption and splenectomy on CD46 transgenic kidney xenograft survival. , 2001, Transplantation proceedings.

[8]  J. Atkinson,et al.  Functional properties of membrane cofactor protein of complement. , 1989, The Biochemical journal.

[9]  A. Menkis,et al.  Porcine bioprosthetic heart valves: The next generation. , 2012, American heart journal.

[10]  R. Pierson,et al.  Clinical lung xenotransplantation – what donor genetic modifications may be necessary? , 2012, Xenotransplantation.

[11]  D. Pinsky.  The Vascular Biology of Heart and Lung Preservation for Transplantation , 1995, Thrombosis and Haemostasis.

[12]  A. D'apice,et al.  The vascular and coagulation issues in xenotransplantation , 2009, Current opinion in organ transplantation.

[13]  Z. Ruggeri,et al.  The role of the porcine von willebrand factor: baboon platelet interactions in pulmonary xenotransplantation , 2002, Transplantation.

[14]  H. Nandurkar,et al.  Pig Thrombomodulin Binds Human Thrombin but Is a Poor Cofactor for Activation of Human Protein C and TAFI , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  J. Schulte am Esch,et al.  Molecular incompatibilities in hemostasis between swine and men--impact on xenografting. , 2001, Annals of transplantation.

[16]  B. Loveland,et al.  Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non‐immunosuppressed baboons , 2004, Xenotransplantation.

[17]  H. Niemann,et al.  Hyperacute rejection in ex vivo‐perfused porcine lungs transgenic for human complement regulatory proteins , 2006, Transplant international : official journal of the European Society for Organ Transplantation.

[18]  T. Starzl,et al.  Production of alpha 1,3-galactosyltransferase-deficient pigs. , 2003, Science.

[19]  P. Cowan.  Coagulation and the xenograft endothelium , 2007, Xenotransplantation.

[20]  I. Wamala,et al.  Up to 9‐day survival and control of thrombocytopenia following alpha1,3‐galactosyl transferase knockout swine liver xenotransplantation in baboons , 2012, Xenotransplantation.

[21]  S. H. A. Chen,et al.  Production of α1,3-Galactosyltransferase-Deficient Pigs , 2002, Science.

[22]  R. Pierson,et al.  Current status of xenotransplantation and prospects for clinical application , 2009, Xenotransplantation.

[23]  B. Reichart,et al.  Transgenic animals in experimental xenotransplantation models: orthotopic heart transplantation in the pig-to-baboon model. , 2007, Transplantation proceedings.

[24]  R. Pierson,et al.  Hyperacute Lung Rejection in the Pig-to-Human Model 4: Evidence for Complement and Antibody Independent Mechanisms , 2005, Transplantation.

[25]  P. Ward,et al.  Protective effects of oligosaccharides in P-selectin-dependent lung injury , 1993, Nature.

[26]  D. Sachs,et al.  Absence of Gal epitope prolongs survival of swine lungs in an ex vivo model of hyperacute rejection , 2011, Xenotransplantation.

[27]  R. Pierson,et al.  Hyperacute rejection is attenuated in GalT knockout swine lungs perfused ex vivo with human blood. , 2005, Transplantation proceedings.

[28]  C. McGregor,et al.  Coagulopathy in α‐galactosyl transferase knockout pulmonary xenotransplants , 2011, Xenotransplantation.

[29]  R. Pierson.  Antibody-mediated xenograft injury: mechanisms and protective strategies. , 2009, Transplant immunology.

[30]  R. Bottino,et al.  Clinical Islet Xenotransplantation , 2012, Diabetes.

[31]  J. Platt,et al.  Disseminated intravascular coagulation in association with pig-to-primate pulmonary xenotransplantation. , 2002, Transplantation.

[32]  Ji-Eun Kim,et al.  Aurintricarboxylic acid upregulates the thrombomodulin expression of endothelial cells and peripheral blood monocytes , 2008, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[33]  Alain Carpentier,et al.  Cardiac xenotransplantation technology provides materials for improved bioprosthetic heart valves. , 2011, The Journal of thoracic and cardiovascular surgery.

[34]  R. Pierson,et al.  Effect of complement fragment 1 esterase inhibition on survival of human decay-accelerating factor pig lungs perfused with human blood. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[35]  John D Lambris,et al.  Role of Membrane Cofactor Protein (CD46) in Regulation of C4b and C3b Deposited on Cells1 , 2002, The Journal of Immunology.

[36]  H. Kang,et al.  Pre‐treatment of porcine pulmonary xenograft with desmopressin: a novel strategy to attenuate platelet activation and systemic intravascular coagulation in an ex‐vivo model of swine‐to‐human pulmonary xenotransplantation , 2008, Xenotransplantation.

[37]  J. Y. Kim,et al.  Aurintricarboxylic acid inhibits endothelial activation, complement activation, and von Willebrand factor secretion in vitro and attenuates hyperacute rejection in an ex vivo model of pig‐to‐human pulmonary xenotransplantation , 2008, Xenotransplantation.

[38]  C. McGregor,et al.  Cardiac xenotransplantation: progress and challenges , 2012, Current opinion in organ transplantation.

[39]  L. Cohn,et al.  Myocardial neutrophil sequestration during reperfusion of the transplanted rabbit heart. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[40]  Ashutosh Kumar Singh,et al.  B‐Cell Depletion Extends the Survival of GTKO.hCD46Tg Pig Heart Xenografts in Baboons for up to 8 Months , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[41]  D. Cooper,et al.  Hepatic Function After Genetically Engineered Pig Liver Transplantation in Baboons , 2010, Transplantation.

[42]  Yifan Dai,et al.  The potential of genetically-engineered pigs in providing an alternative source of organs and cells for transplantation , 2013, Journal of biomedical research.

[43]  J. Platt,et al.  Effect of an Anti-C5a Monoclonal Antibody Indicates a Prominent Role for Anaphylatoxin in Pulmonary Xenograft Dysfunction , 2006, Transplantation.